Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs

The objective of the present study was to determine the cross-protection of Ingelvac PRRS MLV against challenge with the new lineage 1 PRRSV emerged in China in pigs. Two lineage 1 PRRSV strains (FJZ03 and FJWQ16 originated from recombination event between NADC30 and JXA1-like strain). We found that...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Chunhua, Dai, Ailing, Fan, Jialin, Li, Yan, Chen, Anni, Zhou, Xia, Luo, Manlin, Yang, Xiaoyan, Liu, Jiankui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658503/
https://www.ncbi.nlm.nih.gov/pubmed/31346199
http://dx.doi.org/10.1038/s41598-019-47239-9
_version_ 1783438969985302528
author Wei, Chunhua
Dai, Ailing
Fan, Jialin
Li, Yan
Chen, Anni
Zhou, Xia
Luo, Manlin
Yang, Xiaoyan
Liu, Jiankui
author_facet Wei, Chunhua
Dai, Ailing
Fan, Jialin
Li, Yan
Chen, Anni
Zhou, Xia
Luo, Manlin
Yang, Xiaoyan
Liu, Jiankui
author_sort Wei, Chunhua
collection PubMed
description The objective of the present study was to determine the cross-protection of Ingelvac PRRS MLV against challenge with the new lineage 1 PRRSV emerged in China in pigs. Two lineage 1 PRRSV strains (FJZ03 and FJWQ16 originated from recombination event between NADC30 and JXA1-like strain). We found that pigs vaccinated with the vaccine were protected against challenge with the FJZ03 as shown by fewer days of clinical fever, reduced lung pathology scores, lower PRRS virus load in the blood and developed broadly neutralizing antibodies with high titers to FJZ03. In contrast, vaccine provided limited protection against challenge with FJWQ16 with higher fever, lower antibody titers, lower neutralizing antibodies and higher viral loads in blood. These results demonstrate PRRSV-MLV provides incomplete protection against new lineage 1 PRRSVs.
format Online
Article
Text
id pubmed-6658503
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66585032019-07-31 Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs Wei, Chunhua Dai, Ailing Fan, Jialin Li, Yan Chen, Anni Zhou, Xia Luo, Manlin Yang, Xiaoyan Liu, Jiankui Sci Rep Article The objective of the present study was to determine the cross-protection of Ingelvac PRRS MLV against challenge with the new lineage 1 PRRSV emerged in China in pigs. Two lineage 1 PRRSV strains (FJZ03 and FJWQ16 originated from recombination event between NADC30 and JXA1-like strain). We found that pigs vaccinated with the vaccine were protected against challenge with the FJZ03 as shown by fewer days of clinical fever, reduced lung pathology scores, lower PRRS virus load in the blood and developed broadly neutralizing antibodies with high titers to FJZ03. In contrast, vaccine provided limited protection against challenge with FJWQ16 with higher fever, lower antibody titers, lower neutralizing antibodies and higher viral loads in blood. These results demonstrate PRRSV-MLV provides incomplete protection against new lineage 1 PRRSVs. Nature Publishing Group UK 2019-07-25 /pmc/articles/PMC6658503/ /pubmed/31346199 http://dx.doi.org/10.1038/s41598-019-47239-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wei, Chunhua
Dai, Ailing
Fan, Jialin
Li, Yan
Chen, Anni
Zhou, Xia
Luo, Manlin
Yang, Xiaoyan
Liu, Jiankui
Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title_full Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title_fullStr Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title_full_unstemmed Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title_short Efficacy of Type 2 PRRSV vaccine against challenge with the Chinese lineage 1 (NADC30-like) PRRSVs in pigs
title_sort efficacy of type 2 prrsv vaccine against challenge with the chinese lineage 1 (nadc30-like) prrsvs in pigs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658503/
https://www.ncbi.nlm.nih.gov/pubmed/31346199
http://dx.doi.org/10.1038/s41598-019-47239-9
work_keys_str_mv AT weichunhua efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT daiailing efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT fanjialin efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT liyan efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT chenanni efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT zhouxia efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT luomanlin efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT yangxiaoyan efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs
AT liujiankui efficacyoftype2prrsvvaccineagainstchallengewiththechineselineage1nadc30likeprrsvsinpigs

Ejemplares similares